Results
|
1.
|
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. MedStar authors:
Citation: - Lancet Oncology. 14(9):901-8, 2013 Aug.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
All authors: - Blay JY, Chawla S, Choy E, Ferrari S, Grimer R, Henshaw R, Jacobs I, Kroep J, Qian Y, Reichardt P, Rutkowski P, Schuetze S, Seeger L, Skubitz K, Staddon A, Thomas D
|
|
2.
|
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50. MedStar authors:
Year: 2021
Citation: - Journal of Clinical Oncology. 39(21):2339-2349, 2021 07 20.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, Jensen E, Leal TA, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riess JW, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhao B
|
|
3.
|
Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. MedStar authors:
- Alhaj-Moustafa, Muhamad
- Fitzpatrick, Kelly
- Pilla, Ravi
- Vakiti, Anusha
Year: 2019
Citation: - Journal of Oncology Pharmacy Practice. 25(4):1011-1015, 2019 Jun.
Institution:
- MedStar Washington Hospital Center
- Washington Cancer Institute
Department: - Medicine/General Internal Medicine
Medline publication type:
All authors: - Alhaj-Moustafa M, Fitzpatrick KW, Pilla R, Singh D, Vakiti A
|
|
4.
|
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. MedStar authors:
- Alsaadi, Dana
- Charabaty, Aline
- Jennings, Joseph
Year: 2018
Citation: - Journal for Immunotherapy of Cancer. 6(1):142, 2018 Dec 05.
Institution: - MedStar Washington Hospital Center
Department: - Gastroenterology/Hepatology
Medline publication type:
All authors: - Abu-Sbeih H, Ali FS, Alsaadi D, Charabaty A, Gong Z, Jennings J, Luo W, Richards DM, Wang Y
|
|
5.
|
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. MedStar authors:
Year: 2014
Citation: - Journal of Rheumatology. 41(2):300-9, 2014 Feb.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
All authors: - Chatham WW, Freimuth WW, Furie RA, Ginzler EM, LBSL02/99 Study Group, McCune WJ, McKay JD, Merrill JT, Petri MA, Stohl W, Wallace DJ, Weinstein A, Zhong ZJ
|
|
6.
|
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(6):1258-1266, 2020 03 15.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Bolejack V, Burgess M, Davis LE, Hu J, Keung EZ, Lazar AJ, Movva S, Okuno S, Parra Cuentas E, Priebat DA, Reed DR, Reinke DK, Reuben A, Riedel RF, Rodrigues-Canales J, Roland CL, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wang WL, Wargo JA
|
|
7.
|
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(11):1493-1501, 2017 Nov
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Baker LH, Bolejack V, Burgess M, Butterfield LH, Crowley J, D'Angelo S, Davis LE, Hu J, Lazar AJ, Maki RG, Movva S, Okuno SH, Patel S, Priebat DA, Reed DR, Reinke D, Riedel RF, Rodriguez-Canales J, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wistuba II
|
|
8.
|
|
|
9.
|
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors:
Year: 2013
Citation: - Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J
|
|
10.
|
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors:
Year: 2022
Citation: - Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP
|